Big opportunities in big data, but EMA and industry just getting started

PM Live

18 February 2019 - 250m genomes sequenced, but data trapped in silos.

The potential of big data to transform drug development and regulation is now established in biopharma, but Europe’s regulators and industry agree there is a long way to go to make this vision a reality.

That’s because while there has been an explosion in volumes and types of data being generated, a lack of common standards and regulations means these aren’t yet being fully exploited to streamline drug approval or monitoring.

Read PM Live article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Europe , Regulation , Data